Andrew Allen
Founder at GRITSTONE BIO, INC.
Net worth: 6 M $ as of 31/03/2024
Profile
Andrew R.
Allen is the founder of Clovis Oncology, Inc. (founded in 2009) where he held the title of Chief Medical Officer & EVP-Clinical Development from 2011 to 2015.
He is also the founder of Gritstone bio, Inc. (founded in 2015) where he currently holds the titles of President, Chief Executive Officer & Director.
Dr. Allen is also the founder of Revitope Oncology, Inc...
Dr. Allen's current job(s) include being the Chairman at Peptone Ltd.
(since 2023), an Independent Non-Executive Director at Adaptimmune Therapeutics Plc (since 2023), an Independent Director at Verge Analytics, Inc. (since 2021), and a Member at The Royal College of Physicians.
Dr. Allen's former job(s) include being an Independent Director at Sierra Oncology, Inc. (2017-2022), a Director at Nodality, Inc., an Independent Director at Epizyme, Inc. (2014-2021), a Director at Cell Design Labs, Inc. (2015-2017), an Independent Director at TCR2 Therapeutics, Inc. (2018-2023), the Head-Global Project at Abbott Laboratories (2002-2004), the Vice President-Oncology Drug Development at Chiron Corp.
(2004-2006), the Chief Medical Officer & Executive VP-Clinical at Pharmion Corp.
(2006-2008), and a Principal at McKinsey & Co., Inc. (1999-2002).
Dr. Allen's education includes an undergraduate degree from the University of Oxford and a doctorate degree from Imperial College London.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
GRITSTONE BIO, INC.
2.39% | 01/02/2024 | 2,348,620 ( 2.39% ) | 6 M $ | 31/03/2024 |
| 05/07/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Andrew Allen active positions
| Companies | Position | Start |
|---|---|---|
| GRITSTONE BIO, INC. | Founder | 01/08/2015 |
| ADAPTIMMUNE THERAPEUTICS PLC | Director/Board Member | 01/06/2023 |
Verge Analytics, Inc.
 Verge Analytics, Inc. BiotechnologyHealth Technology Verge Analytics, Inc. engages in the provision of biotechnology services. It develops drugs for neurodegenerative diseases using computational genomics. The company was founded by Alice Zhang and Jason Chen in 2015 and is headquartered in San Francisco, CA. | Director/Board Member | 28/09/2021 |
Revitope Oncology, Inc.
 Revitope Oncology, Inc. Hospital/Nursing ManagementHealth Services Revitope Oncology, Inc. develops a programmable antibody circuit pipeline in particular redirecting T cells to tumors. The company was founded by Andrew Allen and Mark Cobbold and is headquartered in Cambridge, MA. | Founder | - |
| The Royal College of Physicians | Corporate Officer/Principal | - |
Peptone Ltd.
 Peptone Ltd. BiotechnologyHealth Technology Peptone Ltd. offers state of the art solutions for protein biotechnology. The firm involves in protein biotechnology research with peer reviewed science, novel use of advanced machine learning and autonomous artificial intelligence. The company was founded by Kamil Tamiola and Matthew Michael Heberling in 2016 and is headquartered in London, the United Kingdom. | Chairman | 28/09/2023 |
Former positions of Andrew Allen
| Companies | Position | End |
|---|---|---|
| TCR2 THERAPEUTICS INC. | Director/Board Member | 01/06/2023 |
| SIERRA ONCOLOGY, INC. | Director/Board Member | 01/07/2022 |
| EPIZYME, INC. | Director/Board Member | 16/11/2021 |
| ░░░░ ░░░░░░ ░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
Training of Andrew Allen
| University of Oxford | Undergraduate Degree |
| Imperial College London | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| GRITSTONE BIO, INC. | Health Technology |
| ADAPTIMMUNE THERAPEUTICS PLC | Health Technology |
| Private companies | 12 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
Pharmion Corp.
 Pharmion Corp. Pharmaceuticals: MajorHealth Technology Pharmion Corp. engages in the development and commercialization of products for the treatment of hematology and oncology patients. It has operations in Switzerland, Israel, and Philippines. The company was founded by Patrick J. Mahaffy in 1999 and is headquartered in Boulder, CO. | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
Nodality, Inc.
 Nodality, Inc. BiotechnologyHealth Technology Nodality, Inc. develops bioinformatics tools to enhance drug development process. Its technology profiles signaling networks in single cells by multiparametric phospho-flow cytometry. The company was founded by Michael C. Needels, Omar D. Perez, Garry P. Nolan and Rodney Weldon Turner in 2003 and is headquartered in San Francisco, CA. | Health Technology |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
Verge Analytics, Inc.
Verge Analytics, Inc. BiotechnologyHealth Technology Verge Analytics, Inc. engages in the provision of biotechnology services. It develops drugs for neurodegenerative diseases using computational genomics. The company was founded by Alice Zhang and Jason Chen in 2015 and is headquartered in San Francisco, CA. | Health Technology |
Revitope Oncology, Inc.
Revitope Oncology, Inc. Hospital/Nursing ManagementHealth Services Revitope Oncology, Inc. develops a programmable antibody circuit pipeline in particular redirecting T cells to tumors. The company was founded by Andrew Allen and Mark Cobbold and is headquartered in Cambridge, MA. | Health Services |
Cell Design Labs, Inc.
 Cell Design Labs, Inc. BiotechnologyHealth Technology Cell Design Labs, Inc. develops disruptive cell-based therapies for cancer and other devastating diseases. The company was founded by Brian G. Atwood and Fred E. Cohen in 2016 and is headquartered in Emeryville, CA. | Health Technology |
TCR2 Therapeutics, Inc.
 TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Peptone Ltd.
Peptone Ltd. BiotechnologyHealth Technology Peptone Ltd. offers state of the art solutions for protein biotechnology. The firm involves in protein biotechnology research with peer reviewed science, novel use of advanced machine learning and autonomous artificial intelligence. The company was founded by Kamil Tamiola and Matthew Michael Heberling in 2016 and is headquartered in London, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Andrew Allen
